Clinical Trials on Drown

Total 457 results

Pacira CryoTech, Inc., a wholly owned subsidiary...

Completed

Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device

Glabellar Frown Lines | Frown Lines

United States
Pacira CryoTech, Inc., a wholly owned subsidiary...

Completed

A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device

Glabellar Frown Lines | Frown Lines

United States
National Institute of Diabetes and Digestive and...

Recruiting

Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism

Brown Adipose Tissue (BAT) Physiology | Phenotyping | Brown Adipocytes

United States
Ain Shams University

Not yet recruiting

Gingival Margin Stability Following Esthetic Crown Lengthening Utilizing a Double Periodontal Surgical Guide

Crown Lengthening

Egypt
Revance Therapeutics, Inc.

Completed

Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)

Frown Lines

United States, Canada
Croma-Pharma GmbH
Hugel

Completed

Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines (H2H)

Frown Lines

United States, Austria, Canada
Aristotle University Of Thessaloniki

Completed

Influence of Restorative Timing on Crown Lengthening Outcome.

Crown Lengthening
Marmara University

Completed

Investigation of the Effect of Stair Activity on Lumbal Paravertebral Mechanical Properties in Amputes.

Stair up and Down, Amputation | Amputation,Stair up and Down

Turkey
Protox Inc.

Not yet recruiting

The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines
Clinical Nutrition Research Centre, Singapore
Institute of Bioengineering and Bioimaging (IBB)

Completed

Brown Adipose Tissue Activation and Energy Expenditure by Capsinoids Stimulation With Trimodality Imaging Using 18-FDG-PET, Fat Fraction MRI and Infrared Thermography (TACTICAL-II)

Brown Adipose Tissue

Singapore
Protox Inc.

Completed

The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Medytox Korea

Completed

A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Ipsen

Completed

Safety and Efficacy Study of Dysport RU and Glabellar Lines

Glabellar Frown Lines

Germany, France
Revance Therapeutics, Inc.

Completed

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

Glabellar Frown Lines

United States, Canada
Medy-Tox

Completed

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

Glabellar Frown Lines

Australia
ATGC Co., Ltd.

Completed

A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines

Glabellar Frown Lines

Korea, Republic of
Yale University
NYU Langone Health

Completed

The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue

Brown Adipose Tissue

United States
Evolus, Inc.
PPD

Completed

Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006 (EV-006)

Glabellar Frown Lines

United States
Evolus, Inc.

Completed

Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines (EV-004)

Glabellar Frown Lines

United States
Evolus, Inc.
PPD

Completed

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002 (EV-002)

Glabellar Frown Lines

United States
Evolus, Inc.
PPD

Completed

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001

Glabellar Frown Lines

United States
Air Force Military Medical University, China

Completed

Basic Study of Fabricating Biomorphic Crowns

Prosthesis | Dental Crown

China
Revance Therapeutics, Inc.

Completed

Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines

Glabellar Frown Lines

Canada
Allergan

Completed

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

Glabellar Frown Lines

United States
Merz Pharmaceuticals GmbH

Completed

NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines (Head2Head)

Glabellar Frown Lines

United Kingdom, Germany, Austria
Pennington Biomedical Research Center

Recruiting

An Examination of Brown Adipose Tissue and Energy Expenditure in Infants (Born2Burn)

Brown Adipose Tissue

United States
Evolus, Inc.
Avania

Recruiting

Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

Glabellar Frown Lines

Germany
Eirion Therapeutics Inc.

Active, not recruiting

AI-09 In Subjects With Glabellar Lines, GL-101

Glabellar Frown Lines

United States
Galderma R&D

Completed

Study Comparing Treatment With Alluzience vs Reconstituted Toxin (STAR)

Glabellar Frown Lines

Germany, United Kingdom
Medytox Korea

Completed

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Evolus, Inc.
ethica Clinical Research Inc.

Completed

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

Treatment of Moderate to Severe Glabellar Lines (READY-1)

Glabellar Frown Lines

United States, Canada
Galderma R&D

Completed

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines

Glabellar Frown Lines

Sweden
Croma-Pharma GmbH

Completed

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II (BLESS-II)

Glabellar Frown Lines
Croma-Pharma GmbH

Completed

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I (BLESS I)

Glabellar Frown Lines
EuBiologics Co.,Ltd

Completed

Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Croma-Pharma GmbH

Completed

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII) (BLESSIII)

Glabellar Frown Lines

United States
Medy-Tox

Unknown

Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®

Glabellar Frown Lines

Korea, Republic of
Medy-Tox

Completed

Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line

Glabellar Frown Lines
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

Germany
Merz Pharmaceuticals GmbH

Completed

Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

Germany
Revance Therapeutics, Inc.

Recruiting

Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines

Glabellar Frown Lines

United States
ATGC Co., Ltd.

Recruiting

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

Glabellar Frown Lines

Korea, Republic of
Galderma R&D

Completed

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

United States
Medy-Tox

Completed

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

Glabellar Frown Lines

Australia
Galderma R&D

Completed

Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

Subject Satisfaction With AbobutulinumtoxinA Treatment (DREAM)

Glabellar Frown Lines

United States
Revance Therapeutics, Inc.

Completed

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

Glabellar Frown Lines

United States

3

Subscribe